Amarin Receives a Buy from Cantor Fitzgerald

By Jason Carr

In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Amarin (NASDAQ: AMRN). The company’s shares opened today at $3.11.

Chen wrote:

“At ESC, Novartis released data from its Phase 3 CANTOS study for ACZ885.”

According to, Chen is ranked 0 out of 5 stars with an average return of -11.2% and a 38.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc.

Amarin has an analyst consensus of Strong Buy, with a price target consensus of $8.50.

The company has a one year high of $4.47 and a one year low of $2.56. Currently, Amarin has an average volume of 2.54M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The company’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.